Welcome to our dedicated page for Elite Pharmaceuticals news (Ticker: ELTP), a resource for investors and traders seeking the latest updates and insights on Elite Pharmaceuticals stock.
Elite Pharmaceuticals, Inc. (OTCQB: ELTP) is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic products, with a focus on oral solid dose formulations. The ELTP news page on Stock Titan aggregates company press releases and related coverage so readers can follow Elite’s disclosures about its operations, products, and regulatory milestones.
Recent news from Elite highlights several key themes. The company regularly reports financial results for its fiscal year and subsequent quarters, noting the impact of lisdexamfetamine product sales and growth in Elite label product lines on revenues and operating income. Elite also announces conference calls to discuss these results, providing dial-in details and inviting stockholder questions in advance.
Product and regulatory developments are another major news category. Elite has reported FDA approval of an Abbreviated New Drug Application for a generic version of Requip XL (Ropinirole Extended-Release Tablets USP) and has announced the commercial launch of a generic version of Percocet (oxycodone hydrochloride and acetaminophen tablets, USP CII). The company has also disclosed positive bioequivalence study results for an undisclosed anticoagulant generic drug product and its intention to file an ANDA with the FDA.
Operational updates, such as the first shipment of product from Elite’s FDA-approved expanded campus in Northvale, New Jersey, and details about its new packaging line, also appear in the news flow. Investors and observers who want a consolidated view of ELTP-related announcements can use this page to review financial updates, FDA and ANDA developments, new product launches, and facility expansion news in one place.
Elite Pharmaceuticals (OTCQB: ELTP) reported third-quarter fiscal 2026 results for the three months ended December 31, 2025. Revenue was $31.6 million, up about 120% year-over-year. Income from operations was $9.0 million, up ~721%. Net income was $18.6 million.
The company attributed the profit increase primarily to sales of newly launched lisdexamfetamine and naltrexone products plus strong growth in Elite-label lines. Management will host a conference call on February 18, 2026 at 11:30 AM EST to discuss results and recent developments.
Elite Pharmaceuticals (OTCQB: ELTP) will release third quarter fiscal 2026 financial results for the period ended December 31, 2025, on Tuesday, February 17, 2026. Management will host a live conference call on Wednesday, February 18, 2026 at 11:30 AM EST to discuss results and provide a business update.
Dial-in details and a conference number are provided; shareholders are asked to submit general and financial questions by specified deadlines. An audio replay will be available online after the call.
Elite Pharmaceuticals (OTCQB: ELTP) reported results for the second quarter of fiscal 2026 ended September 30, 2025. Consolidated revenue was $36.3 million, up approximately 92% year‑over‑year, and income from operations was $8.2 million, up approximately 136% year‑over‑year. Management attributed the operating improvement primarily to sales of newly launched lisdexamfetamine products and broad growth in Elite‑label product lines. Management will host a conference call on November 17, 2025 at 11:30 AM EST; stockholder financial questions were requested by 7:00 PM EST on November 14, 2025. Financial statements are available on the company Form 10‑Q.
Elite Pharmaceuticals (OTCBB: ELTP) announced FDA approval on November 12, 2025 of an ANDA for a generic version of Requip XL (ropinirole XR) in 2 mg, 4 mg, 6 mg, 8 mg and 12 mg strengths.
The product will be marketed under the Elite Laboratories label. According to IQVIA, the branded product and equivalents had $10 million in U.S. sales for the 12 months ended September 2025, providing a measurable commercial reference for potential generic uptake.
Elite Pharmaceuticals (OTCQB: ELTP) will release its second quarter fiscal 2026 financial results for the period ended September 30, 2025 on Friday, November 14, 2025. Management will host a live conference call on Monday, November 17, 2025 at 11:30 AM EST to review financial and operating results and provide a business update. Stockholders are encouraged to submit questions in advance by the stated deadlines.
Call details: domestic dial-in 1-800-346-7359, international 1-973-528-0008, conference number 98840. Audio replay will be available at https://elite.irpass.com/events_presentations.
Elite Pharmaceuticals (OTCQB:ELTP) reported strong financial results for Q1 FY2026 ended June 30, 2025. The company achieved consolidated revenues of $40.2 million, marking a significant 114% increase compared to the same period last year. Operating profits surged to $21.7 million, representing a remarkable 462% growth year-over-year.
The exceptional performance was primarily driven by the successful launch of Elite's lisdexamfetamine products and robust growth across the Elite label product lines. The company has scheduled a conference call for August 15, 2025, at 11:30 AM EDT to discuss these results and provide business updates.
Elite Pharmaceuticals (OTCQB:ELTP), a specialty pharmaceutical company focused on niche generic products, will release its Q1 FY2026 financial results on Thursday, August 14, 2025. The company will host a conference call on Friday, August 15, 2025, at 11:30 AM EDT to discuss financial results and provide a business update.
Shareholders can submit general questions by August 13, 2025 (5:00 PM EDT) and financial questions by August 14, 2025 (7:00 PM EDT) to dianne@elitepharma.com. The call will be accessible via 1-800-346-7359 (domestic) or 1-973-528-0008 (international) using conference number 98840. An audio replay will be available on the company's website.
Elite Pharmaceuticals (OTCQB:ELTP), a specialty pharmaceutical company focused on niche generic products, has reported strong financial results for fiscal year 2025. The company achieved consolidated revenues of $84.0 million, marking a significant 48% increase from the previous fiscal year. Operating profits reached $19.6 million, showing an impressive 81% growth year-over-year.
The substantial improvement in operating performance was primarily driven by the successful launch of Elite's lisdexamfetamine products during Fiscal 2025, along with robust growth in Elite label product lines that were introduced in the previous fiscal year. The company has scheduled a conference call for July 1, 2025, at 11:30 AM EDT to discuss these results and provide business updates.